To study the therapeutic potential of the NF-κB inhibitor BAY11-7082 in the treatment of uveal melanoma in vivo, a xenograft nude mouse model with subcutaneous inoculation of OCM1 cells was established [23–24]. Here, NFKB1 is linked to uveal melanoma.